Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed yesterday at p1,341.00. Pick the ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

GSK PLC GSK shares shed 2.40% to £13.41 Wednesday, on what proved to be an all-around positive trading session for the stock ...

TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Brian Thompson, the CEO of UnitedHealth's insurance unit, was fatally shot in midtown Manhattan last week in what police ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

Inequalities in childhood vaccination are widening in England, with uptake rates of five key vaccines consistently lower in young children living in areas of higher deprivation from 2019 to 2023, ...